COLUMBIA, Maryland and BILLERICA, Massachusetts, February 12 /PRNewswire/ --
- Pay-Per-Patient Pricing Available to Reduce Start-Up Barriers for Cancer Centers
Nucletron, a knowledge-based leader in radiation oncology, and Advanced Radiation Therapy (ART) announced today an exclusive global, strategic partnership to offer the AccuBoost(R) system with the microSelectron(R) high- dose rate (HDR) brachytherapy afterloader treatment delivery solution for the treatment of breast cancer. The partnership will enable clinicians all over the world to deliver boost brachytherapy as part of the whole breast irradiation procedure, providing a superior treatment option with the ultimate goal of improving clinical outcome.
The partnership offers radiation oncology centers the opportunity to implement ART's innovative technology in image-guided HDR breast brachytherapy on a pay-per-patient pricing model, along with a full complement of Nucletron's treatment planning, treatment delivery, training, licensing, reimbursement, and customized service support. ART's expansion of AccuBoost technology through its global partnership with Nucletron will further reduce the barriers to adoption of brachytherapy for cancer centers previously deterred by the initial start-up costs usually associated with implementing a breast brachytherapy program.
We are thrilled to partner with ART and expand the availability and utilization of HDR brachytherapy globally, said Jos Lamers, chief executive officer for Nucletron. Using Nucletron's microSelectron Digital afterloader to deliver AccuBoost technology further reduces the financial, operational, and clinical barriers many cancer centers encounter in providing brachytherapy to their patients. In conjunction with this announcement, Nucletron is offering a pay-per-patient pricing model for centers bundling the AccuBoost treatment option with their new HDR brachytherapy program, allowing these centers to pay for the service when the boost treatment is delivered, providing a more attractive financing model while delivering more treatment options to their patients.
Advanced Radiation Therapy is pleased to partner with Nucletron, stated Piran Sioshansi, Ph.D., president and chief executive officer of ART. Our goal is to make the AccuBoost treatment option available to as many women as possible, all over the world. The market reach and expertise in HDR brachytherapy provided by Nucletron will help us realize this goal. Together we can accelerate the introduction of this new, non-invasive, image-guided procedure to more clinical sites worldwide.
Clinical reports indicate that patients with early stage breast cancer have the best outcomes when the breast conserving lumpectomy procedure is combined with a full course of whole breast irradiation and partial breast boost dose. ART's AccuBoost combines a mammography procedure for real-time image guidance to accurately target the boost dose, and precise dose delivery by Nucletron's microSelectron family of HDR afterloaders. By increasing the accuracy of the dose-targeting and reducing the unintentional exposure to healthy tissue, including the heart, lungs, and skin, AccuBoost is expected to improve patient outcomes, minimizes side effects and result in a better cosmetic results.
Representatives will be on hand to discuss this strategic partnership at the American Brachytherapy Society's School of Breast Brachytherapy and Brachytherapy Physics in San Antonio, TX on February 12-13, and the 2009 ACRO Annual Meeting in Las Vegas, NV on February 26-27.
Nucletron is a knowledge-based leader in Radiation Oncology, working with clinical teams to realize innovative solutions that improve patient care. Nucletron strives to offer the best possible choice of radiation modalities through integrated products, software and services. Critical to the Nucletron philosophy is the establishment of close working relationships with individual clinical teams - reconfiguring traditional boundaries between customer and solution provider. Many Nucletron employees have clinical experience delivering oncology care, providing an in-depth understanding of the complex needs of clinicians. For more information, visit http://www.nucletron.com.
About Advanced Radiation Therapy (ART)
ART is a women's health company dedicated to the advancement of partial breast irradiation with the goal of reducing the cancer recurrence rate and minimizing radiation related complications. ART's AccuBoost system combines real-time, image-guidance with non-invasive, high-dose rate brachytherapy to deliver a focused dose to the lumpectomy site. The AccuBoost technology is based on the premise that the best method to immobilize, image and target breast tissue is via mammography. As such, AccuBoost gives the clinicians the comfort and confidence to see what you treat and treat what you see and significantly reduces the unintentional exposure to the patient's heart and lungs. For more information, visit http://www.AccuBoost.com.
Nucletron B.V. PO Box 930, 3900 AX Veenendaal, The Netherlands, Phone +31(0)318-557133; Media Contact: Danielle Davis, +1-443-834-6725, firstname.lastname@example.org